Nuo Therapeutics, Inc.: Form 10-Q for the period ended Sep 30, 2019
Filed with the SEC on Jan 31, 2020 and accepted by EDGAR at Jan 31, 2020, 21:15 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-07-01 to 2019-09-30 | $57.9k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Revenue | 9 months2019-01-01 to 2019-09-30 | $141.3k | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months2019-07-01 to 2019-09-30 | $34.7k | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2019-01-01 to 2019-09-30 | $97.0k | us-gaap:CostOfRevenue |
| Gross profit | 3 months2019-07-01 to 2019-09-30 | $23.2k | us-gaap:GrossProfit |
| Gross profit | 9 months2019-01-01 to 2019-09-30 | $44.2k | us-gaap:GrossProfit |
| Research and development | 3 months2019-07-01 to 2019-09-30 | $2.7k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2019-01-01 to 2019-09-30 | $181.2k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-07-01 to 2019-09-30 | −$38.7k | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2019-01-01 to 2019-09-30 | −$1.0m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2019-07-01 to 2019-09-30 | −$92.6k | us-gaap:NetIncomeLoss |
| Net income | 9 months2019-01-01 to 2019-09-30 | −$1.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2019-07-01 to 2019-09-30 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2019-01-01 to 2019-09-30 | −$0.05 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-07-01 to 2019-09-30 | $0.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2019-01-01 to 2019-09-30 | −$0.05 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-07-01 to 2019-09-30 | 23,722,400 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2019-01-01 to 2019-09-30 | 23,722,400 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2019-01-01 to 2019-09-30 | −$619.6k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2019-09-30 | $17.3k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-09-30 | $24.0k | us-gaap:AssetsCurrent |
| Total assets | At period end2019-09-30 | $38.5k | us-gaap:Assets |
| Total liabilities | At period end2019-09-30 | $1.3m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-09-30 | −$1.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-20-001481. Last ingested by Listed: Oct 24, 2026, 15:02 ET. Listed shows no prices and gives no investment advice.